Emerging preclinical and clinical data support the role of complement in SCD. Thorough and careful investigation of the efficacy and safety of proximal and distal complement inhibitors in SCD is warranted. This novel pathway has a tremendous potential to pave the way for innovative therapies to prevent and treat SCD complications.
Cowan et al. (Tue,) studied this question.